Sinopharm Tech Holdings (HKSE:08156) Total Liabilities : HK$63.34 Mil (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sinopharm Tech Holdings Total Liabilities?

Sinopharm Tech Holdings's Total Liabilities for the quarter that ended in Dec. 2024 was HK$63.34 Mil.

Sinopharm Tech Holdings's quarterly Total Liabilities increased from Dec. 2023 (HK$228.74 Mil) to Jun. 2024 (HK$250.09 Mil) but then declined from Jun. 2024 (HK$250.09 Mil) to Dec. 2024 (HK$63.34 Mil).

Sinopharm Tech Holdings's annual Total Liabilities declined from Jun. 2022 (HK$250.28 Mil) to Jun. 2023 (HK$213.24 Mil) but then increased from Jun. 2023 (HK$213.24 Mil) to Jun. 2024 (HK$250.09 Mil).

Sinopharm Tech Holdings Total Liabilities Historical Data

The historical data trend for Sinopharm Tech Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Tech Holdings Total Liabilities Chart

Sinopharm Tech Holdings Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

261.56

276.46

250.28

213.24

250.09

Sinopharm Tech Holdings Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															213.24	-	228.74	250.09	63.34

Sinopharm Tech Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sinopharm Tech Holdings's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	249.436	+	(0.653	+	-8.4376949871512E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	250.09

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	44.49	-	-205.599
	=	250.09

Sinopharm Tech Holdings's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	63.193	+	(0.148	+	3.2474023470286E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	63.34

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	44.682	-	-18.659
	=	63.34

Sinopharm Tech Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sinopharm Tech Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Tech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ruttonjee Centre, 11 Duddell Street, Unit 1802, 18th Floor, Ruttonjee House, Hong Kong Central, Hong Kong, HKG

Website

https://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Ltd is an investment holding company. The company's operating segment includes Internet Plus services; Supply chain services; and Manufacturing and distribution of personal protective equipment. It generates maximum revenue from Supply chain services segment, which includes provision of supply chain management, data analysis and related services and trading of related goods, and trading of medial and related products. Geographically, it derives a majority of revenue from Hong Kong.

Executives

Chiu Sin Nang Kenny	2201 Interest of corporation controlled by you
Creative Big Limited	2101 Beneficial owner
Integrated Asset Management (asia) Limited	2101 Beneficial owner
Yam Tak Cheung	2201 Interest of corporation controlled by you
Quantum Worldwide Investment Limited	2101 Beneficial owner
Best Frontier Investments Limited
Chan Kin Ho Philip	2201 Interest of corporation controlled by you
Lam Yui Keung	2201 Interest of corporation controlled by you
Sinopharm Traditional Chinese Medicine Overseas Holdings Limited	2101 Beneficial owner
Main Key Investments Limited	2201 Interest of corporation controlled by you
Guo Lei	2201 Interest of corporation controlled by you
Chan Tung Mei	2202 Interest of your spouse
Cheung Kwai Lan	2201 Interest of corporation controlled by you
Tse Siu Hoi	2101 Beneficial owner
Gam Star China Equity (a Sub-fund Of Gam Star Fund P.l.c.)	2102 Investment manager

Sinopharm Tech Holdings Headlines

No Headlines